Daiichi Sankyo Rolls Out Generics In Japan While Ranbaxy Products Still On Hold In U.S.
This article was originally published in PharmAsia News
Executive SummaryTOKYO - Daiichi Sankyo has initiated operations for its Ranbaxy-supported generics subsidiary in Japan - Daiichi Sanyko Espha - a positive step for the company's established products plans as it awaits news on U.S. FDA action on Ranbaxy
You may also be interested in...
Asia Spotlight: Ranbaxy CEO Arun Sawhney On “Thrilling” Days Of Atorvastatin Approvals And What’s Next
Atorvastatin launch “reinforced the belief in the Indian generic companies,” Sawhney says. Approval of anti-malarial Synriam, the first novel drug developed in India, will lead to “belief that we from India can also develop new products.”
Ranbaxy CEO Arun Sawhney On What’s Next After Lipitor – An Exclusive PharmAsia News Interview (Part 2 of 2)
Ranbaxy Laboratories Ltd. CEO and Managing Director Arun Sawhney stayed away from media interactions for the last four years.